Boya Bio-Pharmaceutical Group Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Boya Bio-Pharmaceutical Group Co., Ltd. - overview
Established
1993
Location
Fuzhou, Jiangxi, China
Primary Industry
Biotechnology
About
Founded in 1993 and based in Fuzhou, China, Boya Bio-Pharmaceutical Group Co. , Ltd. operates as a biopharmaceutical company that focuses on the research, development, production, and sales of blood products. Xinxi Liao, chairman of the company, graduated from China Pharmaceutical University and previously worked for Jiangzhong Pharmaceutical.
It has 5 branch offices. In February 2008, Jiangxi Boya Bio-Pharmaceutical Co. Ltd. raised a pre-IPO funding for CNY 102 million.
In March 2012, the company was listed on the Shenzhen Stock Exchange. The company is mainly engaged in the research, development, production, and sales of blood products, chemical drugs, APIs, biochemical drugs, etc. The products include human albumin, human immunoglobulin, rabies immunoglobulin, etc. The products are suitable for the treatment of tumors, nephrotic syndrome, hemophilia, and other diseases.
The company generates revenue by providing blood products.
Current Investors
GTJA Investment Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.china-boya.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Boya Bio-Pharmaceutical Group Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 227,259,439.8 | 245,238,066.3 | 434,722,135.6 | 539,331,199.9 | 944,978,573.3 | 1,459,983,883.4 | 2,386,943,108.3 | 2,758,912,456.6 | 2,509,678,757.6 | - | - | - |
| % Revenue Growth (YoY) | - | 7.9% | 77.3% | 24.1% | 75.2% | 54.5% | 63.5% | 15.6% | (9.0%) | - | - | - |
| EBITDA (USD) | 88,677,782.4 | 95,944,367.6 | 146,604,311.3 | 218,380,593.3 | 365,757,029.9 | 473,953,915.2 | 639,212,147.4 | 625,448,144.2 | 435,103,846.1 | - | - | - |
| Operating Income (USD) | 71,062,077.5 | 76,754,187.2 | 118,884,911.2 | 185,218,000.3 | 315,776,177.3 | 420,357,871.3 | 572,180,854.7 | 531,506,570.4 | 340,505,694.7 | - | - | - |
| Operating Margin | 31.3% | 31.3% | 27.3% | 34.3% | 33.4% | 28.8% | 24.0% | 19.3% | 13.6% | - | - | - |
| % EBITDA Margin | 39.0% | 39.1% | 33.7% | 40.5% | 38.7% | 32.5% | 26.8% | 22.7% | 17.3% | - | - | - |
| NET Income (USD) | 75,146,190.2 | 82,361,123.2 | 115,204,125.2 | 167,045,137.2 | 277,554,725.6 | 364,931,186.8 | 485,079,636 | 442,123,277.9 | 275,261,495.4 | - | - | - |
| % Net Margin | 33.1% | 33.6% | 26.5% | 31.0% | 29.4% | 25.0% | 20.3% | 16.0% | 11.0% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.